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2015-2016 Influenza Season 
Week 17 ending April 30, 2016 
All data are preliminary and may change as more reports are received. 
 
Synopsis: During week 17 (April 24-30, 2016), influenza activity decreased in the United States. 
o Viral Surveillance: The most frequently identified influenza virus type reported by public 
health laboratories during week 17 was influenza B. The percentage of respiratory 
specimens testing positive for influenza in clinical laboratories decreased. 
o Pneumonia and Influenza Mortality: The proportion of deaths attributed to pneumonia and 
influenza (P&I) was below their system-specific epidemic threshold in both the NCHS 
Mortality Surveillance System and the 122 Cities Mortality Reporting System. 
o Influenza-associated Pediatric Deaths: Four influenza-associated pediatric deaths were 
reported. 
o Influenza-associated Hospitalizations: A cumulative rate for the season of 30.6 
laboratory-confirmed influenza-associated hospitalizations per 100,000 population was 
reported. 
o Outpatient Illness Surveillance: The proportion of outpatient visits for influenza-like illness 
(ILI) was 1.8%, which is below the national baseline of 2.1%. Three of 10 regions reported 
ILI at or above region-specific baseline levels. Puerto Rico and two states experienced 
moderate ILI activity; three states experienced low ILI activity; New York City and 45 states 
experienced minimal ILI activity; and the District of Columbia had insufficient data. 
o Geographic Spread of Influenza: The geographic spread of influenza in Guam, Puerto 
Rico, and 7 states was reported as widespread; 15 states reported regional activity; the 
District of Columbia and 17 states reported local activity; and the U.S. Virgin Islands and 11 
states reported sporadic activity.  
 
National and Regional Summary of Select Surveillance Components 
HHS 
Surveillance 
Regions* 
Data for current week Data cumulative since October 4, 2015 (week 40) 
Out-
patient 
ILI† 
Number of  
jurisdictions 
experiencing 
high or 
moderate ILI 
activity§ 
% respiratory 
specimens 
positive for 
flu in clinical 
laboratories‡ 
A(H1N1)
pdm09 A (H3) 
A 
(Subtyping 
not 
performed) 
B 
Victoria 
lineage 
B 
Yamagata 
lineage 
B lineage 
not 
performed 
Pediatric 
Deaths 
Influenza test results from public health laboratories only 
Nation Normal 3 of 53 11.2% 14,301 3,214 312 1,302 2,904 2,587 64 
Region 1 Normal 0 of 6 16.3% 1,277 114 5 81 46 266 4 
Region 2 Elevated 2 of 4 15.3% 1,141 177 17 127 77 125 5 
Region 3 Elevated 0 of 6 16.9% 2,164 125 44 262 354 125 3 
Region 4 Elevated 0 of 8 11.3% 1,154 245 52 71 63 349 15 
Region 5 Normal 1 of 6 13.1% 2,538 256 86 157 244 51 10 
Region 6 Normal 0 of 5 12.0% 511 358 20 81 121 267 5 
Region 7 Normal 0 of 4 7.9% 457 63 16 35 94 22 1 
Region 8 Normal 0 of 6 10.1% 1,727 371 7 111 527 87 3 
Region 9 Normal 0 of 4 5.7% 2,309 1,325 48 312 1,000 823 16 
Region 10 Normal 0 of 4 11.6% 1,023 180 17 65 378 472 2 
*http://www.hhs.gov/about/agencies/staff-divisions/iea/regional-offices/index.html 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline. 
§ Includes all 50 states, New York City, the District of Columbia, and Puerto Rico 
‡ National data are for current week; regional data are for the most recent three weeks. 
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U.S. Virologic Surveillance: WHO and NREVSS collaborating laboratories, which include both 
public health and clinical laboratories located in all 50 states, Puerto Rico, and the District of 
Columbia, report to CDC the total number of respiratory specimens tested for influenza and the 
number positive for influenza by virus type. In addition, public health laboratories also report the 
influenza A subtype (H1 or H3) and influenza B lineage information of the viruses they test and the 
age or age group of the persons from whom the specimens were collected.   
 
Additional data are available at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
 
The results of tests performed by clinical laboratories are summarized below. 
 
 Week 17 Data Cumulative since October 4, 2015 (week 40) 
No. of specimens tested 12,818 592,547 
No. of positive specimens (%) 1,442 (11.2%) 61,284 (10.3%) 
Positive specimens by type     
Influenza A 550 (38.1%) 42,946 (70.1%) 
Influenza B 892 (61.9%) 18,338 (29.9%) 
 
Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, 
National Summary, 2015-2016 Season 
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The results of tests performed by public health laboratories, as well as the age group distribution of 
influenza positive tests, are summarized below. 
 
 Week 17 Data Cumulative since October 4, 2015 (week 40) 
No. of specimens tested 547 64,479 
No. of positive specimens* 175 24,620 
Positive specimens by type/subtype   
Influenza A 82 (46.9%) 17,827 (72.4%) 
          A(H1N1)pmd09 48 (58.5%) 14,301 (80.2%)
          H3 30 (36.6%) 3,214 (18.0%)
          Subtyping not performed 4 (4.9%) 312 (1.8%)
Influenza B 93 (53.1%) 6,793 (27.6%) 
          Yamagata lineage 37 (39.8%) 2,904 (42.7%)
          Victoria lineage 32 (34.4%) 1,302 (19.2%)
          Lineage not performed 24 (25.8%) 2,587 (38.1%)
*The percent of specimens testing positive for influenza is not reported because public health laboratories often receive samples that have already tested 
positive for influenza at a clinical laboratory and therefore percent positive would not be a valid indicator of influenza activity.  Additional information is 
available at http://www.cdc.gov/flu/weekly/overview.htm 
 
Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, 
National Summary, 2015-2016 Season 
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Age Group Distribution of Influenza Positive Specimens Reported by Public 
Health Laboratories, National Summary, 2015-2016 Season 
Weekly Cumulative
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Age Group Proportions and Total by Influenza Subtype Reported by Public 
Health Laboratories, 2015-2016 Season 
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Influenza Virus Characterization: CDC characterizes influenza viruses through one or more tests 
including genome sequencing, hemagglutination inhibition (HI), and/or neutralization assays. These 
data are used to compare how similar currently circulating influenza viruses are to the reference 
viruses used for developing influenza vaccines, and to monitor for changes in circulating influenza 
viruses. Historically, HI data have been used most commonly to assess the similarity between 
reference viruses and circulating viruses to suggest how well the vaccine may work until such time 
as vaccine effectiveness estimates are available. During the 2014–2015 season and to date this 
season, however, a portion of influenza A (H3N2) viruses do not yield sufficient hemagglutination 
titers for antigenic characterization by HI. For many of these viruses, CDC performs genetic 
characterization to determine the genetic group identity of those viruses. In this way, antigenic 
properties of these viruses can be inferred from viruses within the same genetic group that have 
been characterized antigenically. 
 
CDC has characterized 1,903 influenza viruses [822 A (H1N1)pdm09, 493 A (H3N2), and 588 
influenza B viruses] collected by U.S. laboratories since October 1, 2015. 
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Influenza A Virus [1,315]  
 
 A (H1N1)pdm09 [822]:  821 of 822 (99.9%) influenza A (H1N1)pdm09 viruses were 
antigenically characterized as A/California/7/2009-like, the influenza A (H1N1) component of 
the 2015-2016 Northern Hemisphere vaccine. 
 
 A (H3N2) [493]:  All 493 influenza A (H3N2) viruses were genetically sequenced and all 
viruses belonged to genetic groups for which a majority of viruses antigenically 
characterized were similar to the cell-propagated A/Switzerland/9715293/2013, the influenza 
A (H3N2) reference virus representing the 2015-2016 Northern Hemisphere vaccine 
component. 
o A subset of 223 influenza A (H3N2) viruses also were antigenically characterized; 
215 of 223 (96.4%) H3N2 viruses were A/Switzerland/9715293/2013-like by HI 
testing or neutralization testing. 
 
Influenza B Virus [588]  
 
 Yamagata Lineage [359]: All 359 (100%) influenza B/Yamagata-lineage viruses were 
antigenically characterized as B/Phuket/3073/2013-like, which is included as an influenza B 
component of the 2015-2016 Northern Hemisphere trivalent and quadrivalent influenza 
vaccines. 
 
 Victoria Lineage [229]: 223 of 229 (97.4%) influenza B/Victoria-lineage viruses were 
antigenically characterized as B/Brisbane/60/2008-like, which is included as an influenza B 
component of the 2015-2016 Northern Hemisphere quadrivalent influenza vaccines. 
 
 
2016-2017 Influenza Season – U.S. Influenza Vaccine Composition: The World Health 
Organization (WHO) has recommended vaccine viruses for the 2016-2017 influenza season 
Northern Hemisphere vaccine composition, and the Food and Drug Administration’s Vaccines and 
Related Biological Products Advisory Committee (VRBPAC) has made the vaccine composition 
recommendation to be used in the United States.  Both agencies recommend that trivalent vaccines 
contain an A/California/7/2009 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like 
virus, and a B/Brisbane/60/2008-like (B/Victoria lineage) virus.  It is recommended that quadrivalent 
vaccines, which have two influenza B viruses, contain the viruses recommended for the trivalent 
vaccines, as well as a B/Phuket/3073/2013-like (B/Yamagata lineage) virus. This represents a 
change in the influenza A (H3) component and a change in the influenza B lineage included in the 
trivalent vaccine compared with the composition of the 2015-2016 influenza vaccine. The vaccine 
viruses recommended for inclusion in the 2016-2017 Northern Hemisphere influenza vaccines are 
the same vaccine viruses that were chosen for inclusion in 2016 Southern Hemisphere seasonal flu 
vaccines. These vaccine recommendations were based on several factors, including global 
influenza virologic and epidemiologic surveillance, genetic characterization, antigenic 
characterization, antiviral resistance, and the candidate vaccine viruses that are available for 
production. 
 
  
Antiviral Resistance: Testing of influenza A (H1N1)pdm09, influenza A (H3N2), and influenza B 
virus isolates for resistance to neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) is 
performed at CDC using a functional assay. Additional influenza A (H1N1)pdm09 and influenza A 
(H3N2) clinical samples are tested for mutations of the virus known to confer oseltamivir resistance. 
The data summarized below combine the results of both testing methods. These samples are 
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routinely obtained for surveillance purposes rather than for diagnostic testing of patients suspected 
to be infected with antiviral-resistant virus. 
 
High levels of resistance to the adamantanes (amantadine and rimantadine) persist among 
influenza A (H1N1)pdm09 and influenza A (H3N2) viruses (the adamantanes are not effective 
against influenza B viruses). Therefore, data from adamantane resistance testing are not presented 
below. 
 
Neuraminidase Inhibitor Resistance Testing Results on Samples 
Collected Since October 1, 2015 
 
 
Oseltamivir Zanamivir Peramivir 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Influenza A 
(H1N1)pmd09 1,869 14 (0.7) 908 0 (0.0) 1,869 14 (0.7) 
Influenza A 
(H3N2) 623 0 (0.0) 623 0 (0.0) 556 0 (0.0) 
Influenza B 931 0 (0.0) 931 0 (0.0) 931 0 (0.0) 
 
The majority of recently circulating influenza viruses are susceptible to the neuraminidase inhibitor 
antiviral medications, oseltamivir, zanamivir, and peramivir; however, rare sporadic instances of 
oseltamivir-resistant and peramivir-resistant influenza A (H1N1)pdm09 viruses and oseltamivir-
resistant influenza A (H3N2) viruses have been detected worldwide. Antiviral treatment as early as 
possible is recommended for patients with confirmed or suspected influenza who have severe, 
complicated, or progressive illness; who require hospitalization; or who are at high risk for serious 
influenza-related complications. Additional information on recommendations for treatment and 
chemoprophylaxis of influenza virus infection with antiviral agents is available at 
http://www.cdc.gov/flu/antivirals/index.htm. 
 
 
 
 
Pneumonia and Influenza (P&I) Mortality Surveillance: Rapid tracking of pneumonia and 
influenza-associated deaths is done through two systems, the National Center for Health Statistics 
(NCHS) Mortality Surveillance System and the 122 Cities Mortality Reporting System. NCHS 
mortality surveillance data are presented by the week the death occurred and P&I percentages are 
released two weeks after the week of death to allow for collection of enough data to produce a 
stable P&I percentage. Users of the data should not expect the two systems to produce the same 
percentages, and the percent P&I deaths from each system should be compared to the 
corresponding system-specific baselines and thresholds. 
 
NCHS Mortality Surveillance Data:  
Based on NCHS mortality surveillance data available on May 5, 2016, 7.0% of the deaths occurring 
during the week ending April 16, 2016 (week 15) were due to P&I. This percentage is below the 
epidemic threshold of 7.3% for week 15.  
 
Region and state-specific data are available at http://www.cdc.gov/flu/weekly/nchs.htm. 
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Pneumonia and Influenza Mortality from 
the National Center for Health Statistics Mortality Surveillance System 
Data through the week ending April 16, 2016, as of May 5, 2016  
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122 Cities Mortality Reporting System 
During week 17, 6.8% of all deaths reported through the 122 Cities Mortality Reporting System 
were due to P&I. This percentage was below the epidemic threshold of 6.9% for week 17. 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending April 30, 2016 
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Influenza-Associated Pediatric Mortality: Four influenza-associated pediatric deaths were 
reported to CDC during week 17.  Two deaths were associated with an influenza A (H1N1)pdm09 
virus and occurred during weeks 14 and 15 (the weeks ending April 9, and April 16, 2016).  One 
death was associated with an influenza A virus for which no subtyping was performed and occurred 
during week 13 (the week ending April 2, 2016). One death was associated with an influenza B 
virus and occurred during week 12 (the week ending March 26, 2016).  
 
A total of 64 influenza-associated pediatric deaths have been reported during the 2015-2016 
season from Puerto Rico [1], the District of Columbia [1], Chicago [1], and 28 states (Arizona [3], 
California [10], Colorado [1], Florida [7], Illinois [1], Indiana [2], Kentucky [3], Louisiana [1], Maine 
[1], Maryland, [1], Massachusetts [2], Michigan [1], Minnesota [3], Mississippi [1], Montana [2], 
Nebraska [1], Nevada [3], New Hampshire [1], New Jersey [1], New York [3], North Carolina [1], 
Ohio [1], Oregon [1], Tennessee [3], Texas [4], Virginia [1], Washington [1], and Wisconsin [1]). 
 
Additional data can be found at: http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html. 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
2012-2013 season to present 
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Influenza-Associated Hospitalizations: The Influenza Hospitalization Surveillance Network 
(FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related 
hospitalizations in children younger than 18 years of age (since the 2003-2004 influenza season) 
and adults (since the 2005-2006 influenza season).   
   
The FluSurv-NET covers more than 70 counties in the 10 Emerging Infections Program (EIP) states 
(CA, CO, CT, GA, MD, MN, NM, NY, OR, and TN) and additional Influenza Hospitalization 
Surveillance Project (IHSP) states. The IHSP began during the 2009-2010 season to enhance 
surveillance during the 2009 H1N1 pandemic. IHSP sites included IA, ID, MI, OK and SD during the 
2009-2010 season; ID, MI, OH, OK, RI, and UT during the 2010-2011 season; MI, OH, RI, and UT 
during the 2011-2012 season; IA, MI, OH, RI, and UT during the 2012-2013 season; and MI, OH, 
and UT during the 2013-2014, 2014-15 and 2015-16 seasons.  
 
Data gathered are used to estimate age-specific hospitalization rates on a weekly basis and 
describe characteristics of persons hospitalized with severe influenza illness. The rates provided 
are likely to be an underestimate as influenza-related hospitalizations can be missed, either 
because testing is not performed, or because cases may be attributed to other causes of 
pneumonia or other common influenza-related complications.  
 
Between October 1, 2015 and April 30, 2016, 8,467 laboratory-confirmed influenza-associated 
hospitalizations were reported. The overall hospitalization rate was 30.6 per 100,000 population. 
The highest rate of hospitalization was among adults aged ≥65 years (82.1 per 100,000 population), 
followed by adults aged 50-64 (44.3 per 100,000 population) and children aged 0-4 years (41.4 per 
100,000 population). Among all hospitalizations, 6,370 (75.2%) were associated with influenza A, 
2,017 (23.8%) with influenza B, 42 (0.5%) with influenza A and B co-infection, and 38 (0.5%) had 
no virus type information. Among those with influenza A subtype information, 2,249 (89.0%) were 
A(H1N1)pdm09 and 276 (11.0%) were A(H3N2) virus.  
 
Clinical findings are preliminary and based on 2,285 (26.9%) cases with complete medical chart 
abstraction. The majority (91.2%) of hospitalized adults had at least one reported underlying 
medical condition; the most commonly reported were obesity, cardiovascular disease, metabolic 
disorders and chronic lung disease. There were 341 hospitalized children with complete medical 
chart abstraction; 178 (52.2%) had at least one underlying medical condition. The most commonly 
reported underlying medical conditions among pediatric patients were asthma and neurologic 
disorders. Among the 234 hospitalized women of childbearing age (15-44 years), 55 (23.5%) were 
pregnant. 
 
Additional FluSurv-NET data can be found at: http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html 
and http://gis.cdc.gov/grasp/fluview/FluHospChars.html. 
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Data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), a population-based surveillance for influenza 
related hospitalizations in children and adults in 13 U.S. states. Incidence rates are calculated using the National Center 
for Health Statistics’ (NCHS) population estimates for the counties included in the surveillance catchment area. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
2015-2016 Influenza Season – Week 17, ending April 30, 2016  
 
FluSurv-NET data are preliminary and displayed as they become available.  Therefore, figures are based on varying 
denominators as some variables represent information that may require more time to be collected.  Data are refreshed 
and updated weekly.  Asthma includes a medical diagnosis of asthma or reactive airway disease; Cardiovascular 
diseases include conditions such as coronary heart disease, cardiac valve disorders, congestive heart failure, and 
pulmonary hypertension; does not include isolated hypertension;  Chronic lung diseases include conditions such as 
chronic obstructive pulmonary disease, bronchiolitis obliterans, chronic aspiration pneumonia, and interstitial lung disease; 
Immune suppression includes conditions such as immunoglobulin deficiency, leukemia, lymphoma, HIV/AIDS, and 
individuals taking immunosuppressive medications;  Metabolic disorders include conditions such as diabetes mellitus;  
Neurologic diseases include conditions such as seizure disorders, cerebral palsy, and cognitive dysfunction;  
Neuromuscular diseases include conditions such as multiple sclerosis and muscular dystrophy; Obesity was assigned if 
indicated in patient's medical chart or if body mass index (BMI) >30 kg/m2; Pregnancy percentage calculated using 
number of influenza-positive females aged between 15 and 44 years of age as the denominator; Renal diseases include 
conditions such as acute or chronic renal failure, nephrotic syndrome, glomerulonephritis, and impaired creatinine 
clearance; No known condition indicates that the person did not have any known high risk medical condition indicated in 
medical chart at the time of hospitalization. 
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Outpatient Illness Surveillance: Nationwide during week 17, 1.8% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI). This percentage is below the national baseline of 2.1%. (ILI is defined as 
fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat.) 
 
The increase in the percentage of patient visits for ILI in weeks 51 and 52 (the weeks ending 
December 26, 2015 and January 2, 2016) may have been influenced in part by a reduction in 
routine healthcare visits during the holidays, as has occurred in previous seasons. 
 
Additional data are available at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by 
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
Weekly National Summary, 2015-2016 and Selected Previous Seasons 
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.7% to 3.0% during 
week 17.  Three of 10 regions (Regions 2, 3, and 4) reported a proportion of outpatient visits for ILI 
at or above their region-specific baseline levels.   
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Region 1 - CT, ME, MA, NH, RI, VT
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Region 6 - AR, LA, NM, OK, TX
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Region 3 - DE, DC, MD, PA, VA, WV
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Region 4 - AL, FL, GA, KY, MS, NC, SC, TN
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Region 5 - IL, IN, MI, MN, OH, WI
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Region 7 - IA, KS, MO, NE
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Region 8 - CO, MT, ND, SD, UT, WY
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Region 9 - AZ, CA, HI, NV
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Region 10 - AK, ID, OR, WA
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Region 2 - NJ, NY, PR, USVI
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% ILI Baseline*NOTE: Scales differ between regions
*Use of the regional baselines for state data is not appropriate. 
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2015-2016 Influenza Season – Week 17, ending April 30, 2016  
ILINet State Activity Indicator Map: Data collected in ILINet are used to produce a measure of ILI 
activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI 
and are compared to the average percent of ILI visits that occur during weeks with little or no 
influenza virus circulation. Activity levels range from minimal, which would correspond to ILI activity 
from outpatient clinics being below, or only slightly above, the average, to high, which would 
correspond to ILI activity from outpatient clinics being much higher than average. 
 
During week 17, the following ILI activity levels were experienced: 
 Puerto Rico and two states (Minnesota and New Jersey) experienced moderate ILI activity. 
 Three states (Pennsylvania, Tennessee, and Virginia) experienced low ILI activity. 
 New York City and 45 states (Alabama, Alaska, Arizona, Arkansas, California, Colorado, 
Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, 
Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, 
Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, 
North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, South Carolina, South Dakota, 
Texas, Utah, Vermont, Washington, West Virginia, Wisconsin, and Wyoming) experienced 
minimal ILI activity. 
 Data were insufficient to calculate an ILI activity level from the District of Columbia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This map uses the proportion of outpatient visits to health care providers for influenza-like illness to measure the ILI activity level within a 
state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city 
could cause the state to display high activity levels. 
Data collected in ILINet may disproportionally represent certain populations within a state, and therefore, may not accurately depict the 
full picture of influenza activity for the whole state. 
Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map is based on reports 
from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data are received. 
Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of 
data completeness with data presented by the state likely being the more complete. 
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
influenza viruses, but does not measure the severity of influenza activity. 
  
During week 17, the following influenza activity was reported: 
 Widespread influenza activity was reported by Guam, Puerto Rico, and 7 states 
(Connecticut, Delaware, Maine, New Hampshire, New York, Pennsylvania, and Virginia). 
 Regional influenza activity was reported by 15 states (Alabama, Arizona, California, 
Colorado, Idaho, Iowa, Kentucky, Massachusetts, Missouri, New Jersey, North Carolina, 
Ohio, Oklahoma, Vermont, and Wisconsin). 
 Local influenza activity was reported by the District of Columbia and 17 states (Alaska, 
Arkansas, Hawaii, Maryland, Michigan, Minnesota, Montana, Nebraska, New Mexico, North 
Dakota, Oregon, Rhode Island, South Carolina, South Dakota, Texas, Washington, and 
West Virginia).  
 Sporadic influenza activity was reported by the U.S. Virgin Islands and 11 states (Florida, 
Georgia, Illinois, Indiana, Kansas, Louisiana, Mississippi, Nevada, Tennessee, Utah, and 
Wyoming). 
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Additional National and International Influenza Surveillance Information 
 
FluView Interactive: FluView includes enhanced web-based interactive applications that can provide 
dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications 
allow people to create customized, visual interpretations of influenza data, as well as make comparisons 
across flu seasons, regions, age groups and a variety of other demographics. To access these tools, visit 
http://www.cdc.gov/flu/weekly/fluviewinteractive.htm. 
 
U.S. State, territorial, and local influenza surveillance: Click on a jurisdiction below to access the latest 
local influenza information. 
 
Alabama Alaska Arizona Arkansas California 
Colorado Connecticut Delaware District of Columbia Florida 
Georgia Hawaii Idaho Illinois Indiana 
Iowa Kansas Kentucky Louisiana Maine 
Maryland Massachusetts Michigan Minnesota Mississippi 
Missouri Montana Nebraska Nevada New Hampshire 
New Jersey New Mexico New York North Carolina North Dakota 
Ohio Oklahoma Oregon Pennsylvania Rhode Island 
South Carolina South Dakota Tennessee Texas Utah 
Vermont Virginia Washington West Virginia Wisconsin 
Wyoming New York City Puerto Rico U.S. Virgin Islands 
 
 
World Health Organization: Additional influenza surveillance information from participating WHO member 
nations is available through FluNet and the Global Epidemiology Reports. 
 
WHO Collaborating Centers for Influenza located in Australia, China, Japan, the United Kingdom, and the 
United States (CDC in Atlanta, Georgia). 
 
Europe: For the most recent influenza surveillance information from Europe, please see WHO/Europe and 
the European Centre for Disease Prevention and Control at http://www.flunewseurope.org/  
 
Public Health Agency of Canada: The most up-to-date influenza information from Canada is available at 
http://www.phac-aspc.gc.ca/fluwatch/. 
 
Public Health England: The most up-to-date influenza information from the United Kingdom is available at 
https://www.gov.uk/government/statistics/weekly-national-flu-reports.  
 
Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not 
constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and 
none should be inferred. CDC is not responsible for the content of the individual organization web pages found 
at these links. 
 
An overview of the CDC influenza surveillance system, including methodology and detailed 
descriptions of each data component, is available at: http://www.cdc.gov/flu/weekly/overview.htm.  
 
 
Report prepared: May 6, 2016. 
 
 
 
 
 
